Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have been assigned a consensus rating of “Buy” from the twenty-four brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eighteen have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $155.16.

A number of analysts have recently issued reports on the company. Leerink Swann reiterated a “buy” rating and set a $182.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Raymond James Financial reiterated an “outperform” rating and set a $130.00 target price (down previously from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada boosted their target price on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $0.23 during trading hours on Wednesday, hitting $122.71. The stock had a trading volume of 1,219,200 shares, compared to its average volume of 2,140,000. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34. The stock has a market cap of $27,410.00, a PE ratio of 54.78, a P/E/G ratio of 1.03 and a beta of 1.17.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same quarter in the previous year, the business earned $1.23 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. research analysts expect that Alexion Pharmaceuticals will post 4.82 EPS for the current year.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.35% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC boosted its stake in shares of Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after buying an additional 4,682,336 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Alexion Pharmaceuticals by 7.0% during the 2nd quarter. BlackRock Inc. now owns 19,926,265 shares of the biopharmaceutical company’s stock valued at $2,424,428,000 after buying an additional 1,298,185 shares during the last quarter. Third Point LLC purchased a new position in shares of Alexion Pharmaceuticals during the 2nd quarter valued at approximately $152,088,000. Janus Henderson Group PLC boosted its stake in shares of Alexion Pharmaceuticals by 1,697.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,145,918 shares of the biopharmaceutical company’s stock valued at $139,424,000 after buying an additional 1,082,171 shares during the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Alexion Pharmaceuticals by 42.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock valued at $391,773,000 after buying an additional 955,578 shares during the last quarter. Hedge funds and other institutional investors own 94.26% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Analysts Set Alexion Pharmaceuticals, Inc. (ALXN) PT at $154.67” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/analysts-set-alexion-pharmaceuticals-inc-alxn-pt-at-154-67/1806313.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.